Strategies to Enhance Adoptive Transfer T Cell Clones
增强过继转移 T 细胞克隆的策略
基本信息
- 批准号:7581031
- 负责人:
- 金额:$ 39.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-04-01 至 2010-07-05
- 项目状态:已结题
- 来源:
- 关键词:Adoptive ImmunotherapyAdoptive TransferAntigen TargetingAntigen-Presenting CellsAntigensCD8 AntigensCD8B1 geneCell SurvivalCell TherapyClinicalClinical ResearchClinical TrialsCommunicable DiseasesCulture TechniquesCytomegalovirusCytotoxic T-LymphocytesGoalsGrowthHumanIL2 geneImmuneImmune responseImmunityIn VitroInfectionInfection ControlInfusion proceduresInterleukin-15InterleukinsLymphocyteLymphocyte CountMacaca mulattaMacaca nemestrinaMaintenanceMalignant NeoplasmsModelingMolecular ImmunologyRodent ModelSafetySpecificityT memory cellT-LymphocyteTherapeuticTranslatingTreatment Efficacybasecytokinehuman diseaseimprovedin vivoinsightmigrationnonhuman primateresearch studyresponsetumor
项目摘要
DESCRIPTION (provided by applicant): Studies in rodent models of cancer and infectious diseases have demonstrated that the adoptive transfer of T cells of defined antigen specificity and function can establish or augment an immune response in vivo and provide therapeutic benefit, and there is increasing evidence that adoptive immunotherapy with T cells has therapeutic activity in human malignancies and infection. However, in most clinical studies the infusion of large numbers of cultured T cells or T cell clones has failed to completely eradicate tumors or provide long-term control of infection. This is in part due to the inability with current approaches to establish an immune response of sufficient magnitude and persistence by adoptive transfer for sustained therapeutic efficacy. Studies of cytokines such as IL15 that regulate lymphocyte growth and survival, and of homeostatic mechanisms that operate to maintain lymphocyte numbers but permit expansion of antigen-specific T cells in response to in vivo stimulation have provided insights into strategies that might be employed to better establish T cell immunity by the adoptive transfer of T cell clones. The goals of this proposal are to develop strategies that improve the establishment of a persistent high-level antigen-specific T cell response in vivo by the adoptive transfer of CD8+ T cell clones, and can be applied to clinical trials of T cell therapy for cancer. The studies will be performed in non-human primates (Macacca nemestrina), and utilize CD8+ T cell clones specific for rhesus cytomegalovirus (rhCMV) as a model target antigen. Culture techniques that are routinely used to propagate human T cells for clinical adoptive T cell therapy will be employed to improve our ability to directly translate the results to studies of T cell therapy for human malignancy and infection. The specific aims are:
1). To determine the effect of the in vivo administration of interleukin (IL2) and interleukin 15 (IL15) on the persistence, function, and migration of adoptively transferred CD8+ antigen-specific T cell clones.
2). To determine the effects of lymphodepletion prior to T cell transfer on the persistence, function, and migration of adoptively transferred CD8+ antigen-specific T cell clones.
3). To determine whether the magnitude and persistence of a CD8+ cytotoxic T cell response established by adoptive transfer can be enhanced by antigen stimulation in vivo.
描述(由申请人提供):在癌症和感染性疾病的啮齿动物模型中进行的研究已经证明,具有确定抗原特异性和功能的T细胞的过继转移可以在体内建立或增强免疫应答并提供治疗益处,并且越来越多的证据表明,使用T细胞的过继免疫疗法在人类恶性肿瘤和感染中具有治疗活性。然而,在大多数临床研究中,输注大量培养的T细胞或T细胞克隆未能完全根除肿瘤或提供长期感染控制。这部分是由于目前的方法无法通过过继转移建立足够大小和持久性的免疫应答以获得持续的治疗功效。对调节淋巴细胞生长和存活的细胞因子如IL 15的研究,以及对维持淋巴细胞数量但允许抗原特异性T细胞响应于体内刺激而扩增的稳态机制的研究,提供了对可用于通过T细胞克隆的过继转移更好地建立T细胞免疫的策略的见解。该提案的目标是开发通过过继转移CD8+ T细胞克隆来改善体内持续高水平抗原特异性T细胞应答的建立的策略,并且可以应用于T细胞治疗癌症的临床试验。这些研究将在非人灵长类动物(Macacca nemestrina)中进行,并利用对恒河猴巨细胞病毒(rhCMV)具有特异性的CD8+ T细胞克隆作为模型靶抗原。将采用常规用于增殖用于临床过继性T细胞治疗的人T细胞的培养技术,以提高我们将结果直接转化为人类恶性肿瘤和感染的T细胞治疗研究的能力。具体目标是:
1)。确定体内给予白细胞介素(IL 2)和白细胞介素15(IL 15)对过继转移的CD8+抗原特异性T细胞克隆的持久性、功能和迁移的影响。
2)。确定T细胞转移前淋巴细胞清除对过继转移的CD8+抗原特异性T细胞克隆的持久性、功能和迁移的影响。
3)。确定通过过继转移建立的CD8+细胞毒性T细胞应答的幅度和持久性是否可以通过体内抗原刺激来增强。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STANLEY R. RIDDELL其他文献
STANLEY R. RIDDELL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STANLEY R. RIDDELL', 18)}}的其他基金
Project 2: Targeting Neoantigens for Lung Cancer Immunotherapy
项目2:针对肺癌免疫治疗的新抗原
- 批准号:
10601293 - 财政年份:2019
- 资助金额:
$ 39.64万 - 项目类别:
Project 2: Targeting Neoantigens for Lung Cancer Immunotherapy
项目2:针对肺癌免疫治疗的新抗原
- 批准号:
10174871 - 财政年份:2019
- 资助金额:
$ 39.64万 - 项目类别:
Project 2: Targeting Neoantigens for Lung Cancer Immunotherapy
项目2:针对肺癌免疫治疗的新抗原
- 批准号:
10436174 - 财政年份:2019
- 资助金额:
$ 39.64万 - 项目类别:
Project 2: Targeting Neoantigens for Lung Cancer Immunotherapy
项目2:针对肺癌免疫治疗的新抗原
- 批准号:
10700908 - 财政年份:2019
- 资助金额:
$ 39.64万 - 项目类别:
Targeting Alloreactivity for Leukemia Eradication
针对白血病根除的同种异体反应性
- 批准号:
8277822 - 财政年份:2011
- 资助金额:
$ 39.64万 - 项目类别:
STRATEGIES TO ENHANCE ADOPTIVE TRANSFER OF T CELL CLONES
增强 T 细胞克隆过继转移的策略
- 批准号:
8357607 - 财政年份:2011
- 资助金额:
$ 39.64万 - 项目类别:
STRATEGIES TO ENHANCE ADOPTIVE TRANSFER OF T CELL CLONES
增强 T 细胞克隆过继转移的策略
- 批准号:
8172773 - 财政年份:2010
- 资助金额:
$ 39.64万 - 项目类别:
EVALUATING THE ENGINEERING OF CYTOMEGALOVIRUS-SPECIFIC CD8+ T CELL CLONES
评估巨细胞病毒特异性 CD8 T 细胞克隆的工程设计
- 批准号:
8172786 - 财政年份:2010
- 资助金额:
$ 39.64万 - 项目类别:
Targeted immunotherapy of breast cancer with central memory T cells
中央记忆T细胞对乳腺癌的靶向免疫治疗
- 批准号:
8181485 - 财政年份:2010
- 资助金额:
$ 39.64万 - 项目类别:
STRATEGIES TO ENHANCE ADOPTIVE TRANSFER OF T CELL CLONES
增强 T 细胞克隆过继转移的策略
- 批准号:
7958859 - 财政年份:2009
- 资助金额:
$ 39.64万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 39.64万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 39.64万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 39.64万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 39.64万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 39.64万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 39.64万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 39.64万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 39.64万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 39.64万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 39.64万 - 项目类别: